Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by mercedesmanon Sep 19, 2024 5:37pm
128 Views
Post# 36231988

RE:RE:RE:KRC Insights - FQ3 Update

RE:RE:RE:KRC Insights - FQ3 Update

I'm a little surprised it has seemingly been zero for so long myself. 

The only consolation is that customers should be working off their inventories ( post stocking up during Covid). At some point,  those inventories either run out or expire...and so require replenishment. 


My sense is the next big catalyst will be QuidelOrtho finally getting their act together on the Savanna  

Medium term it's the slow grind up in quarterly profits. Mostly recession proof.  

Medium to long it's all about Kinlytic  


MM 

<< Previous
Bullboard Posts
Next >>